Jazz Pharmaceuticals plc

NASDAQ:JAZZ  
110.27
-2.21 (-1.96%)
5:18:37 PM EDT: $110.27 0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)6.67B
Current PE13.84
Forward PE 23.21
2yr Forward PE 5.11
See more stats
Estimates Current Quarter
Revenue$1.05 Billion
Adjusted EPS-$7.42
See more estimates
10-Day MA$109.77
50-Day MA$108.88
200-Day MA$118.04
See more pivots

Jazz Pharmaceuticals plc Stock, NASDAQ:JAZZ

Waterloo Exchange, Waterloo Road, Dublin, Dublin 4
Ireland
Phone: +353.1.634.7800
Number of Employees: 2800

Description

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.